Systematic review of frontline tyrosine kinase inhibitors for chronic myeloid leukemia
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/egnp7215 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Kevin Leffers und 2 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) accounts for ~15% of newly diagnosed adult leukemias annually. Majority of patients with CML are identified by a translocation between chromosomes 9 and 22 in leukemic cells and are categorized as being Philadelphia chromosome positive (Ph+). This translocation causes the Abelson murine leukemia 1 (ABL1) gene on chromosome 9 and breakpoint cluster region (BCR) gene on chromosome 22 to create a fusion oncogene known as BCR-ABL. The introduction of BCR-ABL tyrosine kinase inhibitors has improved CML management, leading to increased overall survival. Choosing a tyrosine kinase inhibitor requires consideration of established efficacy, side effect profile, patient comorbidities, financial toxicity, and long-term treatment goals.
Zitieren
APA
Leffers, K., Bentivegna, N., & Rim, C. (2026). Systematic review of frontline tyrosine kinase inhibitors for chronic myeloid leukemia. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/egnp7215
Vancouver
Leffers K, Bentivegna N, Rim C. Systematic review of frontline tyrosine kinase inhibitors for chronic myeloid leukemia. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/egnp7215
BibTeX
@article{Leffers2026,
author = {Leffers, Kevin and Bentivegna, Nicole and Rim, Constance},
title = {Systematic review of frontline tyrosine kinase inhibitors for chronic myeloid leukemia},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/egnp7215}
}
EUVIMED